Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Abbott Pulls Briakinumab Application

January 14, 2011 6:51 am | News | Comments

Drug and medical device maker Abbott Laboratories said it withdrew its request for U.S. and European approval of the potential psoriasis drug briakinumab.

TOPICS:

Regulators Approve New Acetadote Formulation

January 14, 2011 6:49 am | News | Comments

Cumberland Pharmaceuticals Inc. said the Food and Drug Administration approved a new formulation of its Acetadote injection used to treat acetaminophen poisoning.

TOPICS:

FDA Orders Less Acetaminophen in Painkillers

January 14, 2011 6:45 am | by Matthew Perrone | News | Comments

Federal health regulators are limiting a key ingredient found in Vicodin, Percocet and other prescription painkillers that have been linked to thousands of cases of liver damage each year.

TOPICS:
Advertisement

Effects of the Emerging Pharmaceutical R & D Model on Informatics

January 14, 2011 4:50 am | by Arjun Bedi, Global Managing Partner, Accenture Health & Life Sciences R&D Practice, Philadelphia, Pa. | Articles | Comments

The need for pharmaceutical R&D organizations to manage expanding volumes of data crucial will require a change in focus and approach.

TOPICS:

Cancer Research UK Signs AstraZeneca Deal

January 13, 2011 6:33 am | News | Comments

Cancer Research UK’s drug development office has signed a Strategic Combinations Alliance with AstraZeneca to take combinations of experimental cancer drugs into early phase clinical trials.

TOPICS:

Vaccine Markets A Refuge for Big Pharma

January 13, 2011 6:29 am | News | Comments

Irked by weakened pipelines and growing pressure from patent expiries, the big pharma majors such as AstraZeneca and Pfizer found vaccines industry as safe avenue to invest and register guaranteed revenues.

TOPICS:

Researchers Show How One Gene Becomes Two

January 13, 2011 6:22 am | News | Comments

Researchers report that they are the first to show in molecular detail how one gene evolved two competing functions that eventually split up – via gene duplication – to pursue their separate destinies.

TOPICS:

Coffee Increases Levels of Diabetes-Protective Protein

January 13, 2011 6:18 am | News | Comments

Coffee, that morning elixir, may give us an early jump-start to the day, but numerous studies have shown that it also may be protective against type 2 diabetes. Yet no one has really understood why.

TOPICS:
Advertisement

Nabriva Finalizes Recruitment in Phase 2 ABSSSI Trial

January 13, 2011 6:13 am | News | Comments

Nabriva Therapeutics, a biotechnology company focused on developing a new class of antibiotics for serious infections caused by resistant pathogens, has completed recruitment of a Phase 2 clinical trial of BC-3781 in acute bacterial skin and skin structure infections.

TOPICS:

OncoMed Begins Dosing In Cancer Trial

January 13, 2011 6:10 am | News | Comments

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, announced that patient dosing has commenced in a Phase 1 clinical trial of OMP-59R5 in patients with advanced solid tumor cancers.

TOPICS:

Folotyn Drives Allos Revenue Growth

January 13, 2011 5:46 am | News | Comments

Allos Therapeutics Inc. said that sales of the lymphoma drug Folotyn drove revenue in the fourth quarter and it will cut 13 percent of its staff. The company said it expects to report revenue of $11.7 million, which tops Wall Street estimates.

TOPICS:

Genzyme Revenue Falls Short in 4Q

January 13, 2011 5:40 am | News | Comments

Genzyme Corp. said that it expects to report revenue growth in the fourth quarter, but the preliminary results fell short of expectations. The drugmaker also trimmed its outlook for 2011 as it continues recovering from manufacturing problems.

TOPICS:

Watson Meets Earning Estimates

January 13, 2011 5:33 am | News | Comments

Watson Pharmaceuticals Inc. said Wednesday its 2010 results were about equal to its expectations. The company said its earnings will be at the midpoint of its estimated range of $3.37 to $3.45 per share.

TOPICS:

Oregon Sues J & J Over Recall

January 13, 2011 5:30 am | News | Comments

Oregon Attorney General John Kroger has sued Johnson & Johnson and two subsidiaries, claiming consumers were exposed to defective supplies of Motrin by a delay in public disclosure of a recall.

TOPICS:

FDA Panel Votes No on Liprotamase

January 13, 2011 5:27 am | News | Comments

Drugmaker Eli Lilly and Co. Inc. said a panel of federal health advisers voted against an experimental treatment designed to aid digestion in patients with cystic fibrosis and other diseases that affect the pancreas.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading